Uterus Cervix - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Diagnose benign or malignant diseases affecting female reproductive organs

₹699₹1,500

53% OFF

Uterus Cervix - Large Biopsy 3-6 cm: Comprehensive Medical Test Information Guide

1. Why is it done?
- Test Purpose: This test involves the collection and histopathological examination of a large cervical tissue specimen (3-6 cm) to diagnose abnormal cellular changes and detect cervical pathology including dysplasia, carcinoma, and other benign or malignant lesions.
- Primary Indications: Abnormal Pap smear results (ASCUS, LSIL, HSIL, SCC), HPV-positive status, visible cervical lesions or abnormalities on colposcopy, persistent cervicitis, abnormal vaginal bleeding, suspected cervical cancer or dysplasia, evaluation of cervical polyps or masses, and follow-up of previously treated cervical lesions.
- Timing and Circumstances: Typically performed during colposcopy examination when direct visualization reveals significant abnormalities, usually 1-3 weeks after abnormal screening results, not during menstruation to avoid contamination, and preferably when adequate visualization of the cervical lesion is possible.
2. Normal Range
- Normal Findings: Normal cervical tissue histology shows intact stratified squamous epithelium, normal columnar endocervical cells, intact basement membrane, absence of dysplasia, normal inflammatory response, no evidence of malignancy, and preserved tissue architecture without koilocytosis.
- Result Interpretation: Negative - Normal tissue architecture, no dysplasia or malignancy; Positive - Evidence of dysplasia or malignancy; Borderline/Benign - Inflammatory changes, infection, or HPV effect without dysplasia.
- Classification System: Results are reported using the CIN grading system (CIN 1, CIN 2, CIN 3) or WHO/Bethesda classification, categorizing findings by severity and dysplasia level.
3. Interpretation
- Benign Findings: Normal cervical epithelium, chronic inflammation, infectious processes (HPV effect without dysplasia, yeast, bacteria), squamous metaplasia, polyps, or cysts. Clinical significance: reassuring, may require monitoring if HPV-related changes present.
- Low-Grade Dysplasia (CIN 1/LSIL): Abnormal cells limited to lower third of epithelium, often HPV-associated, relatively low malignant potential. Clinical significance: usually spontaneously regresses in 70-80% of cases; requires close follow-up and possible repeat colposcopy.
- High-Grade Dysplasia (CIN 2-3/HSIL): Abnormal cells extending to middle or upper third of epithelium, significant architectural disarray, increased mitotic activity. Clinical significance: increased risk of progression to invasive cancer; treatment typically recommended (excisional or ablative procedures).
- Carcinoma (Invasive): Malignant cells breaching basement membrane into underlying stroma, may be squamous cell carcinoma, adenocarcinoma, or other types. Clinical significance: requires immediate oncologic consultation, staging studies, and treatment planning.
- Factors Affecting Results: HPV type and viral load, specimen adequacy and orientation, presence of inflammation or infection, menstrual cycle phase, previous treatment or procedures, immunosuppression status, smoking history, and adequate fixation and processing.
4. Associated Organs
- Primary Organ: Cervix uteri - part of the lower uterine segment connecting the uterus to the vagina, lined with stratified squamous epithelium at the ectocervix and columnar epithelium at the endocervix.
- Associated Conditions: Cervical dysplasia (CIN 1, 2, 3), cervical cancer (squamous cell carcinoma, adenocarcinoma), cervicitis, polyps, fibroids, adenomyosis extending to cervix, endometrial conditions extending downward, and vaginal extension of lesions.
- Diseases Diagnosed/Monitored: Human Papillomavirus (HPV) infection, cervical intraepithelial neoplasia (CIN), invasive cervical cancer, recurrent cervicitis, herpes simplex virus (HSV) infection, and post-treatment surveillance of cervical lesions.
- Potential Complications: If abnormalities confirmed: progression to invasive cancer if untreated, metastatic spread to lymph nodes, pelvic organs, and distant sites, cervical stenosis following treatment, infertility or pregnancy complications after cervical procedures, recurrent dysplasia, and infection of biopsy site.
5. Follow-up Tests
- Based on Normal Results: Routine cervical cancer screening per guidelines (Pap smear, HPV testing, or co-testing), repeat colposcopy if indicated by prior abnormal cytology, HPV testing if HPV-related changes noted.
- Based on CIN 1/Low-Grade Results: HPV testing and typing, repeat colposcopy in 12 months, follow-up Pap smear or liquid-based cytology in 3-6 months, consideration of excisional procedure if persistent, imaging if invasive features suspected.
- Based on CIN 2-3/High-Grade Results: Excisional treatment (loop electrosurgical excision, cold knife conization, or laser conization) to establish margins and rule out invasive disease, HPV testing post-treatment, colposcopy follow-up, surveillance Pap smears for 25 years.
- Based on Invasive Carcinoma: MRI or CT imaging for staging, pelvic ultrasound, chest imaging, tumor markers (SCC antigen, HPV DNA quantitation), oncology consultation, fertility assessment if age-appropriate, treatment planning (surgery, chemotherapy, radiation).
- Surveillance and Monitoring: Post-treatment: colposcopy every 3-6 months for first 2 years, then annually; liquid-based cytology or HPV testing per protocol; extended monitoring for 20-25 years; annual screening indefinitely.
- Complementary Tests: Reflex HPV testing, p16/Ki-67 immunostaining, HPV typing and viral load quantitation, immunohistochemistry markers, repeat biopsy if clinically indicated.
6. Fasting Required?
- Fasting Requirement: No - Fasting is NOT required for cervical biopsy.
- Pre-Procedure Preparation: Schedule procedure during follicular phase of menstrual cycle (days 5-25 of cycle) to optimize visualization and avoid menstrual contamination, avoid sexual intercourse 24-48 hours prior, avoid douching or vaginal medications for 24 hours before procedure, empty bladder and bowel before colposcopy, wear comfortable, easily removable clothing.
- Medication Instructions: Continue regular medications as prescribed; aspirin, NSAIDs, and anticoagulants may be continued unless otherwise directed by provider; if excessive bleeding risk, discuss with clinician prior to procedure.
- Additional Requirements: Informed consent required, baseline vital signs obtained, pregnancy test may be required if status unknown, review of medication allergies and adverse reactions, discussion of risks/benefits, pain management options reviewed (local anesthetic typically applied to cervix).
- Post-Procedure Instructions: Expect vaginal bleeding or spotting for 2-4 weeks; avoid tampons and use pads instead; avoid sexual intercourse for 2-4 weeks; avoid douching for 2-4 weeks; avoid strenuous exercise for several days; report excessive bleeding, severe pain, fever, or foul-smelling discharge; acetaminophen or ibuprofen may be used for discomfort.

How our test process works!